偉創電氣(688698.SH):8月以來取得5項發明專利、3項實用新型專利、2項外觀專利
格隆匯12月28日丨偉創電氣(688698.SH)公佈,公司自2021年8月起至今,公司取得國家知識產權局頒發的專利證書10項,其中發明專利5項、實用新型專利3項、外觀專利2項。
5項發明專利為:交流永磁同步電機的保護方法及裝置、一種負載自適應方法、感應電機定子電阻啟動辨識方法、辨識設備參數的方法和設備、變頻器死區鉗位補償方法以及補償系統。
3項實用新型專利為:雙極性輸出線性穩壓電源、變頻器、PLC和伺服控制系統、一種分層式佈局變頻器 、一種温度採樣系統、變頻器和伺服控制系統。
2項外觀專利為:可編程邏輯控制器(PLC-VC系列)、伺服電機(帶剎車)。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.